银屑病中特异性核抗原自身抗体及司库奇尤单抗的降低作用
该研究用线性免疫印迹法检测201例银屑病和银屑病关节炎患者及50例健康对照对23种核抗原的抗体反应,发现20.4%银屑病患者至少对1种抗原反应,最常见为DFS70(6.5%)。司库奇尤单抗诱导缓解后抗DFS70等自身抗体随时间下降,而病原体抗体无下降,自身抗体减少与浆母细胞、滤泡B细胞和滤泡T细胞显著减少相关。
要点
- 银屑病患者中20.4%存在至少1种核抗原自身抗体,DFS70最常见(6.5%)。
- 司库奇尤单抗缓解后核抗原自身抗体下降,病原体抗体无下降。
- 自身抗体减少与浆母细胞、滤泡B细胞和滤泡T细胞显著减少相关。
核心结论
- 银屑病中约三分之一抗原特异性ANA患者识别DFS70。
- 司库奇尤单抗降低核抗原自身反应性、浆母细胞、滤泡B细胞和滤泡T细胞,提示其新作用机制。
研究设计与样本
- 共纳入201例患者(101例银屑病、100例银屑病关节炎)和50例ANA阴性健康对照。
- 用线性免疫印迹法检测对23种核抗原的抗体反应。
- 评估司库奇尤单抗(抗IL-17A)治疗对ANA水平的影响。
主要发现
- 至少对1种抗原抗体反应见于20.4%银屑病患者(银屑病25.7%、银屑病关节炎15%),健康对照8%(p = ns)。
- 最常见自身抗体针对DFS70(6.5%)。
- 司库奇尤单抗诱导缓解后,抗DFS70及其他抗原特异性自身抗体随时间下降。
- 针对巨细胞病毒、EB病毒和幽门螺杆菌抗原的IgG抗体未见下降。
- 自身抗体下降与浆母细胞、滤泡B细胞和滤泡T细胞显著减少相关。
关键数值与推荐
- 银屑病患者至少1种核抗原抗体阳性率20.4%(银屑病25.7%、银屑病关节炎15%),健康对照8%(p = ns)。
- 抗DFS70抗体阳性率6.5%。
临床怎么用
- 银屑病患者可检测核抗原特异性自身抗体,DFS70为常见靶点。
- 司库奇尤单抗治疗缓解后核抗原自身抗体下降,可结合浆母细胞和滤泡辅助细胞变化评估免疫调节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-nuclear antibodies (ANA) are frequently detected in patients with psoriasis (Ps) and psoriatic arthritis (PsA), but their target autoantigens remain unknown. We assessed antibody (ab) reactivity against 23 known nuclear antigens in patients with Ps and PsA and assess the effects of secukinumab (anti-IL17A) treatment on ANA levels. A total of 201 patients, 101 with Ps and 100 with PsA, and 50 ANA-negative healthy controls (HCs) were tested for ANAs by a line immunoassay testing reactivity to 23 nuclear antigens. Ab reactivity to at least 1 antigen was found in 20.4% psoriatic disease patients (25.7% Ps and 15% PsA) compared to 8% HCs (p = ns), the most frequent being against dense fine speckled 70 (DFS70) (6.5%). In Ps and PsA patients with secukinumab-induced remission, anti-DFS70 and other antigen-specific autoantibodies were diminished over time. No decline was noted for IgG abs against antigens from pathogens such as cytomegalovirus, Epstein-Barr virus and Helicobacter pylori. Autoantibody decrease was associated with significant reduction of plasmablasts, follicular B and follicular T cells. In conclusion, one third of antigen-specific ANA patients with psoriatic disease recognize DFS70. Secukinumab decreases nuclear antigen autoreactivity, plasmablasts, follicular B and follicular T cells, highlighting a new mechanism of its action.
引用
- Patrikiou E, Liaskos C, Mavropoulos A, et al. Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab. Clin Chim Acta. 2020. PMID: 32710943. doi:10.1016/j.cca.2020.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。